Galectin Therapeutics (GALT) Reports Q2 Loss of $0.21
Tweet
Share
E-mailGalectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.21), versus ($0.17) reported last year.
For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Berenberg Starts Brooks Macdonald Group PLC (BRK:LN) at Buy
- FactSet Research Systems (FDS) PT Raised to $253 at Jefferies
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
